Drug Profile

NBI 1117570

Alternative Names: Dual M1/M4 agonist - Neurocrine Biosciences; Dual muscarinic M1/M4 agonist - Nxera Pharma; NBI-1117570; NBI-570

Latest Information Update: 26 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sosei Heptares
Developer Neurocrine Biosciences; Nxera Pharma
Class Antipsychotics; Small molecules
Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I CNS disorders

Most Recent Events

14 Jan 2025 Neurocrine plans to initiate a phase II trail in schizophrenia, in the second half of 2025
31 Mar 2024 Sosei Heptares is now called Nxera Pharma
12 Sep 2023 Phase-I clinical trials in CNS disorders (In adults, In volunteers) in USA (PO) (Sosei Heptares pipeline, September 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com